| EMA number | EMEA/H/C/000135 |
| ATC code | N04BC05 |
| Authorisation | 27 October 1997 |
| Withdrawn | 2 February 2006 |
| Revision | 5 |
DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i.e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).